BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
NIH-HESI Workshop: Assessing Emerging Cell and Gene Therapies for Disease-Specific Therapeutic Applications
December 2 - December 3
ARMI | BioFabUSA will participate in the upcoming National Institutes of Health (NIH) and Health and Environmental Sciences Institute (HESI) workshop, Assessing Emerging Cell and Gene Therapies for Disease-Specific Therapeutic Applications: In Vivo Tracking and Biodistribution.
Dr. Richard McFarland, ARMI’s Chief Regulatory Officer, will serve as a panel moderator, contributing to discussions focused on advancing scientific understanding, cross-sector collaboration, and the development of cell and gene therapies.
This two-day workshop brings together experts from government, academia, industry, and other stakeholder organizations to examine the current state of in vivo tracking and biodistribution technologies across preclinical and clinical applications.
Workshop Highlights
Topics will include:
- Current approaches to tracking the localization, persistence, and fate of cell and gene therapies.
- Technical challenges and emerging imaging technologies.
- Regulatory and public health considerations.
- Opportunities to strengthen translation from preclinical research to clinical applications.
- Future research priorities, funding opportunities, and industry-government-academic collaboration.
The workshop will feature presentations, panel discussions, and breakout sessions designed to identify scientific and technical gaps and opportunities to advance cell and gene therapy development.
Registration: Learn More & Register
Organizer: National Institutes of Health (NIH) and Health and Environmental Sciences Institute (HESI Global).
